LLY is trading at +2.6% now at $1054.62, bucking broader market weakness where the S&P 500 is down 0.09% and NASDAQ is down 0.39%.
- BofA Securities lowered its price target to $1268 from $1286 on December 15, 2025, while keeping a Buy rating, though recent analyst targets have mostly risen.
- The significant gain occurs without major company-specific catalysts like earnings or drug approvals reported today.
- The stock's performance contrasts with broader tech pressures and AI concerns affecting the NASDAQ.